Evidence map›Paper›PMID 37964169›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2024

Chitosan nanoparticles encapsulating farnesol evaluated in vivo against Candida albicans.

Adelaide Fernandes Costa, Jacqueline Teixeira da Silva, Juliana Assis Martins, Viviane Lopes Rocha, Liliana Borges de Menezes, Andre Correa Amaral

Open access · greenAbstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Chitosan nanoparticles encapsulating farnesol show potent antifungal activity against Candida albicans biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  2. Review
  3. Journal of fungi (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Adelaide Fernandes CostaBiotechnology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil. adelaidefernandes@ufg.br.ORCID http://orcid.org/0000-0002-7947-7236
Jacqueline Teixeira da SilvaBiotechnology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil.
Juliana Assis MartinsBiotechnology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil.
Viviane Lopes RochaBiotechnology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil.
Liliana Borges de MenezesBiotechnology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil.
Andre Correa AmaralBiotechnology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil.
Universidade Federal de Goiás · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Farnesol is a natural essential oil with antimicrobial properties. Complexation of farnesol in chitosan nanoparticles can be useful to improve its bioavailability and potentiate its antifungal capabilities such as inhibition of hyphal and biofilm formation. The aim of this study was to develop and characterize chitosan nanoparticles with farnesol (NF) and evaluate their toxicity and antifungal action on C. albicans in vivo. The NF were prepared by the ionic gelation method and showed physicochemical characteristics such as diameter less than 200 nm, monodisperse distribution, positive zeta potential, spherical morphology, and stability after 120 days of storage. In the evaluation of toxicity in Galleria mellonella, NF did not reduce the survival rate, indicating that there was no toxicity in vivo at the doses tested. In the assays with G. mellonella infected by C. albicans, the larvae treated with NF had a high survival rate after 48 h, with a significant reduction of the fungal load and inhibition of the formation of biofilms and hyphae. In the murine model of vulvovaginal candidiasis (VVC), histopathological analysis showed a reduction in inflammatory parameters, fungal burden, and hyphal inhibition in mice treated with NF. The produced nanoparticles can be a promising alternative to inhibit C. albicans infection.

Indexed as

ChitosanNanoparticlesAnimalsAntifungal AgentsBiofilmsCandida albicansFarnesolMiceAntifungal AgentsChitosanFarnesolChitosanFarnesolGalleria mellonellaNanotechnology

Identifiers

PMID37964169
PMCPMC10920512
OpenAlexW4388653574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.